IN8bio, Inc. announced the appointment of Corinne Epperly, MD, MPH, to its Board of Directors. Dr. Epperly will serve on IN8bio?s Compensation Committee as well as its Science & Technology Committee. She will work closely with the management team to provide guidance on strategic, operational, scientific, and clinical matters related to the Company?s pipeline of gamma-delta T cell therapies.

With over two decades of experience in oncology as a physician and a scientist, Dr. Epperly uniquely combines her medical expertise with business and financial acumen. She has spent 15 years in leadership roles with a successful track record in oncology drug development and launches. Before joining IN8bio, Dr. Epperly most recently served as the Chief Operating Officer of CARGO Therapeutics, where she was a key player in CARGO?s formation and the advancement of its next-generation CAR-T cell therapies for cancer patients.

Her prior roles include Senior Vice President, Strategy and Operations of Iovance Biotherapeutics and leadership roles at Bristol Myers Squibb, where she played a pivotal role in the launch of OPDIVO® across multiple indications.